Literature DB >> 21326812

Large and round tumor nuclei in osteosarcoma: good clinical outcome.

Carlos E de Andrea1, Antonio Sergio Petrilli, Reynaldo Jesus-Garcia, Luiz F Bleggi-Torres, Maria Teresa S Alves.   

Abstract

Osteosarcoma is the most frequent primary malignant bone tumor. Distinct histological features are distinguishable based on the morphology of the tumor. Differences in nuclei size and shape are often observed in osteosarcoma reflecting its broad histopathological heterogeneity. This study explores the relevance of two nuclear parameters in osteosarcoma: large area and round shape. Computerized nuclear morphometry was performed in 56 conventional osteosarcoma preoperative biopsies. The mean patient follow-up time was 35.1 months. Based on the nuclear area, no significant difference (P = 0.09) in overall survival between patients with large (> 42.5 μm(2)) and small (< 42.5 μm(2)) tumor nuclei was found. However, when cases with large and round nuclei were analyzed jointly (> 42.5 μm(2) and coefficient of nuclear roundness > 0.7), these two parameters together were likely to be a predictive factor (P = 0.05). Osteosarcoma patients with large and round tumor nuclei had a better outcome than patients with small and polymorphic (ovoid or spindle-shaped) nuclei. In this study, nuclear morphometry proved to be a useful tool to shed light on the biology of osteosarcoma showing that some morphometric parameters can be easily applied to help identifying patients with a good prognosis.

Entities:  

Keywords:  Large nuclei; nuclear morphometry; osteosarcoma; round nuclei

Mesh:

Year:  2011        PMID: 21326812      PMCID: PMC3037203     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  12 in total

1.  Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder.

Authors:  Marco G W Bol; Jan P A Baak; Simon Rep; Willem L Marx; Arnold Jan Kruse; Siebe D Bos; Otto Kisman; Feja J Voorhorst
Journal:  Urology       Date:  2002-12       Impact factor: 2.649

2.  Osteosarcoma of bone.

Authors:  K K Unni
Journal:  J Orthop Sci       Date:  1998       Impact factor: 1.601

3.  Anaplastic osteosarcoma with abundant eosinophilic cytoplasm and minimal osteoid production.

Authors:  T Yamamoto; T Marui; K Mizuno; T Kizaki; R Minami; K Hanioka; Y Hayashi
Journal:  Pathol Int       Date:  2000-07       Impact factor: 2.534

4.  Small cell osteosarcoma. A clinicopathologic study of 27 cases.

Authors:  A G Ayala; J Y Ro; A K Raymond; N Jaffe; S Chawla; H Carrasco; M Link; J Jimenez; J Edeiken; S Wallace
Journal:  Cancer       Date:  1989-11-15       Impact factor: 6.860

5.  Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup.

Authors:  E I Hauben; S Weeden; J Pringle; E A Van Marck; P C W Hogendoorn
Journal:  Eur J Cancer       Date:  2002-06       Impact factor: 9.162

Review 6.  Prognostic factors in localized extremity osteosarcoma: a systematic review.

Authors:  J A M Bramer; J H van Linge; R J Grimer; R J P M Scholten
Journal:  Eur J Surg Oncol       Date:  2009-02-20       Impact factor: 4.424

7.  The role of nuclear morphometry in prediction of prognosis for rhabdomyosarcoma in children.

Authors:  B Kazanowska; M Jelen; A Reich; W Tarnawski; A Chybicka
Journal:  Histopathology       Date:  2004-10       Impact factor: 5.087

8.  Histological grading and morphometric analysis of cartilaginous tumours.

Authors:  T Ishida; F Kikuchi; R Machinami
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

9.  Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry.

Authors:  Robert W Veltri; M Craig Miller; Sumit Isharwal; Cameron Marlow; Danil V Makarov; Alan W Partin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-01       Impact factor: 4.254

10.  Nuclear polymorphism in osteosarcomas as a prognostic factor for the effect of chemotherapy. A quantitative study.

Authors:  R Apel; G Delling; H Krumme; K Winkler; M Salzer-Kuntschik
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985
View more
  5 in total

1.  Research findings working with the p53 and Rb1 targeted osteosarcoma mouse model.

Authors:  Yaojuan Lu; Steven Gitelis; Guanghua Lei; Ming Ding; Carl Maki; Ranim R Mira; Qiping Zheng
Journal:  Am J Cancer Res       Date:  2014-05-26       Impact factor: 6.166

2.  Melorheostosis: A Clinical, Pathologic, and Radiologic Case Series.

Authors:  Cameron N Fick; Nadja Fratzl-Zelman; Paul Roschger; Klaus Klaushofer; Smita Jha; Joan C Marini; Timothy Bhattacharyya
Journal:  Am J Surg Pathol       Date:  2019-11       Impact factor: 6.394

3.  Development of on-chip multi-imaging flow cytometry for identification of imaging biomarkers of clustered circulating tumor cells.

Authors:  Hyonchol Kim; Hideyuki Terazono; Yoshiyasu Nakamura; Kazuko Sakai; Akihiro Hattori; Masao Odaka; Mathias Girault; Tokuzo Arao; Kazuto Nishio; Yohei Miyagi; Kenji Yasuda
Journal:  PLoS One       Date:  2014-08-20       Impact factor: 3.240

4.  A nuclear circularity-based classifier for diagnostic distinction of desmoplastic from spindle cell melanoma in digitized histological images.

Authors:  Manuel Schöchlin; Stephanie E Weissinger; Arnd R Brandes; Markus Herrmann; Peter Möller; Jochen K Lennerz
Journal:  J Pathol Inform       Date:  2014-10-21

5.  Chemical Interrogation of Nuclear Size Identifies Compounds with Cancer Cell Line-Specific Effects on Migration and Invasion.

Authors:  Sylvain Tollis; Andrea Rizzotto; Nhan T Pham; Sonja Koivukoski; Aishwarya Sivakumar; Steven Shave; Jan Wildenhain; Nikolaj Zuleger; Jeremy T Keys; Jayne Culley; Yijing Zheng; Jan Lammerding; Neil O Carragher; Valerie G Brunton; Leena Latonen; Manfred Auer; Mike Tyers; Eric C Schirmer
Journal:  ACS Chem Biol       Date:  2022-02-24       Impact factor: 5.100

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.